Patents by Inventor Eliane Piaggio
Eliane Piaggio has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230201264Abstract: The present invention relates to an engineered immune cell defective for Suv39h1. Preferably, said engineered immune cell further comprises a genetically engineered antigen receptor that specifically binds a target antigen. The present invention also relates to a method for obtaining a genetically engineered immune cell comprising a step consisting in inhibiting the expression and/or activity of Suv39h1 in the immune cell; and further optionally comprising a step consisting in introducing in the said immune cell a genetically engineered antigen receptor that specifically binds to a target antigen. The invention also encompasses said engineered immune cell for their use in adoptive therapy, notably for the treatment of cancer.Type: ApplicationFiled: March 2, 2023Publication date: June 29, 2023Inventors: Sebastian AMIGORENA, Eliane PIAGGIO, Christel GOUDOT, Luigia PACE, Genevieve ALMOUZNI
-
Publication number: 20230149512Abstract: The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and/or inflammatory diseases.Type: ApplicationFiled: January 6, 2023Publication date: May 18, 2023Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale), Assistance Publique - Hopitaux De Paris, SORBONNE UNIVERSITEInventors: David KLATZMANN, David SAADOUN, Patrice CACOUB, Michèle ROSENZWAJG, Eliane PIAGGIO, Gilbert BENSIMON, Claude BERNARD
-
Patent number: 11622978Abstract: The present invention relates to an engineered immune cell defective for Suv39h1. Preferably, said engineered immune cell further comprises a genetically engineered antigen receptor that specifically binds a target antigen. The present invention also relates to a method for obtaining a genetically engineered immune cell comprising a step consisting in inhibiting the expression and/or activity of Suv39h1 in the immune cell; and further optionally comprising a step consisting in introducing in the said immune cell a genetically engineered antigen receptor that specifically binds to a target antigen. The invention also encompasses said engineered immune cell for their use in adoptive therapy, notably for the treatment of cancer.Type: GrantFiled: January 20, 2020Date of Patent: April 11, 2023Assignees: INSTITUT CURIE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)Inventors: Sebastian Amigorena, Eliane Piaggio, Christel Goudot, Luigia Pace, Genevieve Almouzni, Leticia Niborski
-
Publication number: 20230107291Abstract: The invention relates to a method of identification of functional disease-specific, in particular tumor-specific, regulatory T cells and markers thereof. The invention also relates to the derived functional tumor-specific regulatory T cells, markers and engineered regulatory T cells and to their use for the diagnosis, prognosis, monitoring and treatment of cancer.Type: ApplicationFiled: February 22, 2021Publication date: April 6, 2023Applicants: Institut Curie, Institut National de la Santé et de la Recherche Médicale, Institut Mutualiste MontsourisInventors: Eliane Piaggio, Wilfrid Richer, Christine Sedlik, Jimena Tosello, Joshua Waterfall, Elisa Bonnin
-
Patent number: 11559566Abstract: The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and/or inflammatory diseases.Type: GrantFiled: July 10, 2020Date of Patent: January 24, 2023Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, SORBONNE UNIVERSITEInventors: David Klatzmann, David Saadoun, Patrice Cacoub, Michèle Rosenzwajg, Eliane Piaggio, Gilbert Bensimon, Claude Bernard
-
Publication number: 20220193198Abstract: The invention relates to Interleukin-2 (IL-2) variants for the prevention or treatment of immune disorders, including with no limitations allergic, autoimmune, chronic or acute inflammatory and infectious diseases; graft-versus-host disease; graft rejection and cancer. The invention also relates to the use of said IL-2 variants for the screening of anti-IL-2 antibodies with pro-T-effector or pro-T-regulatory cell activity.Type: ApplicationFiled: March 27, 2020Publication date: June 23, 2022Applicants: Institut Curie, Institut National de la Sante et de la Recherche Medicale, Institut Pasteur, Centre National de la Recherche ScientifiqueInventors: Eliane PIAGGIO, Sebastian AMIGORENA, Pamela CAUDANA, Felix REY, Gleyder ROMAN-SOSA, Pablo GUARDADO-CALVO
-
Patent number: 11285176Abstract: The present invention relates to an engineered immune cell defective for Suv39h1. Preferably, said engineered immune cell further comprises a genetically engineered antigen receptor that specifically binds a target antigen. The present invention also relates to a method for obtaining a genetically engineered immune cell comprising a step consisting in inhibiting the expression and/or activity of Suv39h1 in the immune cell; and further optionally comprising a step consisting in introducing in the said immune cell a genetically engineered antigen receptor that specifically binds to a target antigen. The invention also encompasses said engineered immune cell for their use in adoptive therapy, notably for the treatment of cancer.Type: GrantFiled: October 21, 2021Date of Patent: March 29, 2022Assignees: INSTITUT CURIE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRSInventors: Sebastian Amigorena, Eliane Piaggio, Christel Goudot, Luigia Pace, Genevieve Almouzni, Leticia Niborski
-
Publication number: 20220040235Abstract: The present invention relates to an engineered immune cell defective for Suv39h1. Preferably, said engineered immune cell further comprises a genetically engineered antigen receptor that specifically binds a target antigen. The present invention also relates to a method for obtaining a genetically engineered immune cell comprising a step consisting in inhibiting the expression and/or activity of Suv39h1 in the immune cell; and further optionally comprising a step consisting in introducing in the said immune cell a genetically engineered antigen receptor that specifically binds to a target antigen. The invention also encompasses said engineered immune cell for their use in adoptive therapy, notably for the treatment of cancer.Type: ApplicationFiled: October 21, 2021Publication date: February 10, 2022Inventors: Sebastian AMIGORENA, Eliane PIAGGIO, Christel GOUDOT, Luigia PACE, Genevieve ALMOUZNI
-
Publication number: 20210038691Abstract: The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and/or inflammatory diseases.Type: ApplicationFiled: July 10, 2020Publication date: February 11, 2021Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale), ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, SORBONNE UNIVERSITEInventors: David Klatzmann, David SAADOUN, Patrice CACOUB, Michèle ROSENZWAJG, Eliane PIAGGIO, Gilbert BENSIMON, Claude BERNARD
-
Patent number: 10765723Abstract: The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and/or inflammatory diseases.Type: GrantFiled: March 22, 2019Date of Patent: September 8, 2020Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale, Assistance Publique—Hopitaux De Paris, SORBONNE UNIVERSITEInventors: David Klatzmann, David Saadoun, Patrice Cacoub, Michèle Rosenzwajg, Eliane Piaggio, Gilbert Bensimon, Claude Bernard
-
Publication number: 20200171090Abstract: The present invention relates to an engineered immune cell defective for Suv39h1. Preferably, said engineered immune cell further comprises a genetically engineered antigen receptor that specifically binds a target antigen. The present invention also relates to a method for obtaining a genetically engineered immune cell comprising a step consisting in inhibiting the expression and/or activity of Suv39h1 in the immune cell; and further optionally comprising a step consisting in introducing in the said immune cell a genetically engineered antigen receptor that specifically binds to a target antigen. The invention also encompasses said engineered immune cell for their use in adoptive therapy, notably for the treatment of cancer.Type: ApplicationFiled: January 20, 2020Publication date: June 4, 2020Inventors: Sebastian AMIGORENA, Eliane PIAGGIO, Christel GOUDOT, Luigia PACE, Genevieve ALMOUZNI
-
Publication number: 20200157225Abstract: The present invention relates to an inhibitor of H3K9 histone methyl transferase SUV39H1 for use in combination with at least one immune checkpoint modulator in the treatment of cancer.Type: ApplicationFiled: January 27, 2020Publication date: May 21, 2020Inventors: Sebastian AMIGORENA, Eliane PIAGGIO, Leticia NIBORSKI
-
Publication number: 20200147099Abstract: The present invention relates to an inhibitor of H3K9 histone methyl transferase SUV39H1 for use in combination with at least one immune checkpoint modulator in the treatment of cancer.Type: ApplicationFiled: June 20, 2018Publication date: May 14, 2020Inventors: Sebastian AMIGORENA, Eliane PIAGGIO, Leticia NIBORSKI
-
Patent number: 10576103Abstract: The present invention relates to an engineered immune cell defective for Suv39h1. Preferably, said engineered immune cell further comprises a genetically engineered antigen receptor that specifically binds a target antigen. The present invention also relates to a method for obtaining a genetically engineered immune cell comprising a step consisting in inhibiting the expression and/or activity of Suv39h1 in the immune cell; and further optionally comprising a step consisting in introducing in the said immune cell a genetically engineered antigen receptor that specifically binds to a target antigen. The invention also encompasses said engineered immune cell for their use in adoptive therapy, notably for the treatment of cancer.Type: GrantFiled: May 29, 2019Date of Patent: March 3, 2020Assignees: INSTITUT CURIE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALS (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRSInventors: Sebastian Amigorena, Eliane Piaggio, Christel Goudot, Luigia Pace, Genevieve Almouzni
-
Publication number: 20190365807Abstract: The present invention relates to an engineered immune cell defective for Suv39h1. Preferably, said engineered immune cell further comprises a genetically engineered antigen receptor that specifically binds a target antigen. The present invention also relates to a method for obtaining a genetically engineered immune cell comprising a step consisting in inhibiting the expression and/or activity of Suv39h1 in the immune cell; and further optionally comprising a step consisting in introducing in the said immune cell a genetically engineered antigen receptor that specifically binds to a target antigen. The invention also encompasses said engineered immune cell for their use in adoptive therapy, notably for the treatment of cancer.Type: ApplicationFiled: May 29, 2019Publication date: December 5, 2019Inventors: Sebastian AMIGORENA, Eliane PIAGGIO, Christel GOUDOT, Luigia PACE, Genevieve ALMOUZNI
-
Publication number: 20190351023Abstract: The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and/or inflammatory diseases.Type: ApplicationFiled: March 22, 2019Publication date: November 21, 2019Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale), Assistance Publique - Hopitaux De Paris, SORBONNE UNIVERSITEInventors: David Klatzmann, David Saadoun, Patrice Cacoub, Michèle Rosenzwajg, Eliane Piaggio, Gilbert Bensimon, Claude Bernard
-
Patent number: 10293028Abstract: The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and/or inflammatory diseases.Type: GrantFiled: May 5, 2017Date of Patent: May 21, 2019Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Assistance Publique—Hopitaux De Paris, SORBONNE UNIVERSITEInventors: David Klatzmann, David Saadoun, Patrice Cacoub, Michéle Rosenzwajg, Eliane Piaggio, Gilbert Bensimon, Claude Bernard
-
Publication number: 20190056392Abstract: An in vitro method for determining whether a patient has, or is at risk of having or developing an autoimmune disease or for assessing the severity or predicting the outcome of an autoimmune disease, comprising a step of detecting or quantifying in a biological sample obtained from said patient an immune anti-IL2 response, peptides specifically recognised by anti-1L2 antibodies or IL-2-specific T cells of T1D, systemic lupus erythematosus, rheumatoid arthritis, Sjögren's syndrome and autoimmune polymyositis patients, and pharmaceutical compositions.Type: ApplicationFiled: September 27, 2018Publication date: February 21, 2019Inventors: Eliane PIAGGIO, Louis PEROL
-
Patent number: 10183061Abstract: The present invention relates to the boosting of Treg cells for the treatment of Alzheimer's disease and related disorders.Type: GrantFiled: June 20, 2014Date of Patent: January 22, 2019Assignees: ICM (INSTITUT DU CERVEAU ET DE LA MOELLE EPINIERE), APHP (ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSERM (INSTITUT NATIONAL DE LA RECHERCHE MEDICALE), SORBONNE UNIVERSITEInventors: Guillaume Dorothee, Eliane Piaggio, Dylla Ait Ahmed, Pierre Aucouturier
-
Patent number: 10114018Abstract: An in vitro method for determining whether a patient has, or is at risk of having or developing an autoimmune disease or for assessing the severity or predicting the outcome of an autoimmune disease, comprising a step of detecting or quantifying in a biological sample obtained from said patient an immune anti-IL2 response, peptides specifically recognized by anti-IL2 antibodies or IL-2-specific T cells of T1D, systemic lupus erythematosus, rheumatoid arthritis, Sjögren's syndrome and autoimmune polymyositis patients, and pharmaceutical compositions.Type: GrantFiled: April 21, 2015Date of Patent: October 30, 2018Inventors: Eliane Piaggio, Louis Perol